UK Space Agency
UK government agency funding civil and commercial space activity.
Last refreshed: 1 May 2026
What is the UK Space Agency doing to make in-space drug manufacturing commercially viable?
- What does the UK Space Agency actually do?
- UKSA coordinates and funds British civil and commercial space activity. It contributes to international programmes like Galileo and ExoMars, licenses commercial launches, funds research contracts, and co-authors regulatory pathways for emerging sectors like in-space manufacturing.Source: GOV.UK
- How does the UK Space Agency support space startups?
- UKSA offers direct contracts (such as the £250,000 PHARM study to BioOrbit), commissioning frameworks (such as the NSOC space surveillance contracts won by Spaceflux), and co-authoring joint regulatory pathways that give startups a clear licensing route.Source: GOV.UK
- What is the NSOC and who runs it?
- The National Space Operations Centre (NSOC) is a UK Government space surveillance and tracking framework commissioned by UKSA. In April 2026, Spaceflux won all three multi-year NSOC contracts, becoming the operational backbone of UK orbital surveillance.Source: GeoConnexion
- Is the UK Space Agency part of the European Space Agency?
- No. UKSA is a UK executive agency under DSIT. The UK remains a member state of the European Space Agency (ESA) and contributes to ESA programmes including ExoMars. It rejoined the Galileo satellite navigation programme as a third-country participant after post-Brexit negotiations.Source: GOV.UK
Background
The UK Space Agency (UKSA) is an executive agency of the Department for Science, Innovation and Technology (DSIT), established in April 2010 to consolidate British civil space activity under a single national body. Its annual budget runs to approximately £600 million, funding a broad portfolio that spans satellite navigation contributions to the EU's Galileo replacement programme (the UK rejoined as a third-country participant following post-Brexit negotiations), the ExoMars rover programme in partnership with the European Space Agency, national Earth observation and climate-data programmes, and the commercial launch licensing regime that underpins the UK's ambition to host the first European orbital launch. The agency operates as a coordinator across government, industry, and academia rather than as a direct operator: it funds, regulates, and convenes rather than building hardware itself.
In March 2026, UKSA co-published a joint pathway with the MHRA, the Regulatory Innovation Office, and the Civil Aviation Authority establishing a regulatory route for space-manufactured pharmaceutical products, naming BioOrbit as the pioneering commercial case . The same month, the agency awarded BioOrbit a £250,000 contract under the PHARM (Pharmaceutical Manufacturing in Microgravity) study for regulatory-compliant in-orbit mission design. Separately, it commissioned the National Space Operations Centre (NSOC) framework, a multi-year space surveillance and tracking programme that Spaceflux swept in its entirety in April 2026 .
UKSA's broader significance is as an instrument of regulatory commercialisation: it does not act alone but convenes the agencies whose sign-off commercial operators need. The PHARM pathway, which combined UKSA, MHRA, CAA, and RIO in a single joint instrument, exemplifies an approach the FCA Innovation Hub pioneered in fintech. If UKSA applies the same model across in-space manufacturing, launch licensing, and orbital surveillance, the UK's competitive advantage in space commercialisation will rest primarily on regulatory speed rather than public capital.